Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002740322 | SCV003004778 | uncertain significance | Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria | 2022-04-19 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with arginine, which is basic and polar, at codon 41 of the SUCLA2 protein (p.His41Arg). This variant is present in population databases (rs753558884, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with SUCLA2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002721382 | SCV003696197 | uncertain significance | Inborn genetic diseases | 2022-05-11 | criteria provided, single submitter | clinical testing | The c.122A>G (p.H41R) alteration is located in exon 2 (coding exon 2) of the SUCLA2 gene. This alteration results from a A to G substitution at nucleotide position 122, causing the histidine (H) at amino acid position 41 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |